目的 探討安羅替尼聯(lián)合TP方案治療老年非小細(xì)胞肺癌患者的效果及其對(duì)CA125、MALAT1水平的影響。方法 選取2019年5月-2019年12月青島市婦女兒童醫(yī)院和青島市市立醫(yī)院治療的非小細(xì)胞肺癌患者98例作為研究對(duì)象，將患者隨機(jī)分為對(duì)照組和觀察組，每組各49例。對(duì)照組患者治療第1天將紫杉醇注射液135 mg/m²溶于生理鹽水500 mL靜脈滴注，3 h內(nèi)完成。在治療1~3 d后將順鉑注射液溶于生理鹽水250 mL中靜脈滴注，1 h完成。治療21 d作為1個(gè)周期，治療3個(gè)周期。觀察組患者在對(duì)照組的基礎(chǔ)上服用鹽酸安羅替尼膠囊，12 mg/次，1次/d，服用2周后休息1周，治療共計(jì)3個(gè)周期。觀察兩組的臨床療效，同時(shí)比較兩組治療前后的CA125、MALAT1水平及免疫功能指標(biāo)。結(jié)果 治療后，觀察組患者的腫瘤控制率為46.94%，顯著高于對(duì)照組的26.53%（P<0.05）。治療后，兩組CA125水平顯著降低，MALAT1水平顯著升高（P<0.05）；且觀察組患者的CA125顯著低于對(duì)照組，MALAT1顯著高于對(duì)照組（P<0.05）。治療后，兩組患者的CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺比值及NK細(xì)胞均顯著下降（P<0.05）；觀察組患者CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺比值及NK細(xì)胞顯著高于對(duì)照組（P<0.05）。結(jié)論 安羅替尼聯(lián)合TP方案化療治療非小細(xì)胞肺癌效果顯著，可顯著改善患者CA125水平及MALAT1的表達(dá)，安全性較好。

Objective To investigate the effect of anlotinib combined with TP chemotherapy in treatment of elderly patients with nonsmall cell lung cancer and the influence on the levels of CA125 and MALAT1. Methods A total of 98 patients with NSCLC who were treated in Qingdao Women's and Children's Hospital and Qingdao Municipal Hospital from May 2019 to December 2019 were selected as the research subjects, and the patients were randomly divided into control group and observation group, with 49 patients in each group. Patients in the control group were iv administered with Paclitaxel Injection, 135 mg/m² dissolved in 500 mL normal saline intravenously on the first day of treatment, which was completed within 3 h. After 1 to 3 days of treatment, Cisplatin Injection was dissolved in 250 mL of normal saline and intravenously dripping, which was completed in 1 h. The treatment lasted for 21 d as one cycle, and the treatment lasted for 3 cycles. Patients in the observation group were po administered with Anlotinib Hydrochloride Capsules on the basis of control group, 12 mg/time, once daily. The treatment lasted for 3 months after 2 weeks of treatment with 1 week rest. The clinical efficacy of two groups was observed, and the levels of CA125, MALAT1 and immune function were compared before and after treatment. Results After treatment, the tumor control rate of observation group was 46.94%, significantly higher than 26.53% of control group (P<0.05). After treatment, the level of CA125 in two groups was significantly decreased, but MALAT1 level was significantly increased (P<0.05). After treatment, the level of CA125 in observation group was significantly lower than control group, but MALAT1 was significantly higher than control group (P<0.05). After treatment, the ratio of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and the percentage of NK cells in two groups were significantly decreased (P<0.05). The ratio of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK cell percentage in observation group were significantly higher than those in control group (P<0.05). Conclusion Amlotinib combined with TP chemotherapy has a significant effect in treatment of NSCLC, which can significantly improve the level of CA125 and the expression of MALAT1 in patients with good safety.

R971